Investor Firms Urge MoonLake Holders to Meet Dec. 15 Lead-Plaintiff Deadline
The suits accuse MoonLake of overstating sonelokimab's advantages after Phase 3 results sent the stock down nearly 90%.
Overview
- Rosen Law Firm, The Schall Law Firm, and DJS Law Group issued notices inviting MLTX investors to seek lead-plaintiff status by December 15, 2025.
- The putative class period spans purchases made from March 10, 2024 through September 29, 2025.
- Complaints allege MoonLake falsely promoted SLK as superior to monoclonal antibodies without proven advantages.
- Rosen’s notice cites claims about Nanobody-related tissue penetration and efficacy that allegedly did not translate into superior clinical benefit.
- The firms reference Phase 3 results described by analysts as disastrous, after which MoonLake's shares fell nearly 90%, and they note no class has been certified yet.